EdwinPalmerRockMDPhD

PubMed

• 38 citations
  Role of Fcγ receptors in HER2-targeted breast cancer therapy.
  Antonino Musolino, William J Gradishar, Hope S Rugo, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram> ;Journal for Immunotherapy of Cancer. 2022 Jan 1
• 177 citations
  Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
  Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-R...> ;JAMA Oncology. 2021 Apr 1
• 38 citations
  A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
  Anthony W. Tolcher, Keith T. Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas E. Witzig, Thomas M. Habermann, Andrea J. Bullock, Edwin P. Rock, Agnes Elekes, Chest...> ;The Oncologist. 2018 Jun 1
• 108 citations
  Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
  Hagop M. Kantarjian, Gail J. Roboz, Patricia Kropf, Karen W.L. Yee, Casey O'Connell, Raoul Tibes, Katherine Walsh, Nikolai A. Podoltsev, Elizabeth A. Griffiths, Elias ...> ;The Lancet. Oncology. 2017 Oct 1
• 39 citations
  Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
  T.R.J. Evans, E. Van Cutsem, Malcolm J. Moore, Igor Bazin, Alexander S. Rosemurgy, G. Bodoky, G. Deplanque, M. Harrison, Bohuslav Melichar, D. Pezet, A. Elekes, Edwin ...> ;Annals of Oncology. 2017 Feb 1
• 10 citations
  Dosing algorithm revisit for busulfan following IV infusion
  Yanlin Wang, Kazunobu Kato, Christopher Le Gallo, Elizabeth Armstrong, Edwin P. Rock, Xiaofeng Wang> ;Cancer Chemotherapy and Pharmacology. 2015 Jan 6
• 83 citations
  Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
  Johanna C. Bendell, David S. Hong, Howard A. Burris, Aung Naing, Suzanne F. Jones, Gerald S. Falchook, Patricia Bricmont, Agnes Elekes, Edwin P. Rock, Razelle Kurzrock> ;Cancer Chemotherapy and Pharmacology. 2014 May 13
• 5 citations
  GCP data quality for early clinical development.
  Edwin P. Rock, Vernette J. Molloy, Jeffrey S. Humphrey> ;Clinical Cancer Research. 2010 Mar 15
• 62 citations
  Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
  Edwin P. Rock, John Finkle, Howard J. Fingert, Brian Booth, Christine Garnett, Stephen Grant, Robert Justice, Richard J. Kovacs, Peter R. Kowey, Ignacio Rodriguez, Wen...> ;American Heart Journal. 2009 May 1
• 22 citations
  Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy
  Maitreyee Hazarika, Edwin P. Rock, Gene M. Williams, Ramzi Dagher, Rajeshwari Sridhara, Brian Booth, Ann T. Farrell, Robert Justice, Richard Pazdur> ;The Oncologist. 2008 Oct 1
• 39 citations
  Patient-reported outcomes supporting anticancer product approvals.
  Edwin P. Rock, Dianne L. Kennedy, Melissa H. Furness, William F. Pierce, Richard Pazdur, Laurie B. Burke> ;Journal of Clinical Oncology. 2007 Nov 10
• 106 citations
  Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward
  Joseph Lipscomb, Bryce B. Reeve, Steven B. Clauser, Jeffrey S. Abrams, Deborah Watkins Bruner, Laurie B. Burke, Andrea Denicoff, Patricia A. Ganz, Kathleen Gondek, Lor...> ;Journal of Clinical Oncology. 2007 Nov 10
• 508 citations
  Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective
  Donald L. Patrick, Laurie B. Burke, John H. Powers, Jane Scott, Edwin P. Rock, Sahar Dawisha, Robert T. O'Neill, Dianne L. Kennedy> ;Value in Health. 2007 Nov 1
• 22 citations
  Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products
  Edwin P. Rock, Jane Scott, Dianne L. Kennedy, Rajeshwari Sridhara, Richard Pazdur, Laurie B. Burke> ;Journal of the National Cancer Institute. Monographs. 2007 Oct 1
• 363 citations
  Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
  Vicki L. Goodman, Edwin P. Rock, Ramzi Dagher, Roshni Ramchandani, Sophia Abraham, Jogarao V. S. Gobburu, Brian Booth, S. Leigh Verbois, David E. Morse, Cheng Yi Liang...> ;Clinical Cancer Research. 2007 Mar 1
• 198 citations
  Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
  Edwin P. Rock, Vicki L. Goodman, Janet X. Jiang, Kooros Mahjoob, S. Leigh Verbois, David L. Morse, Ramzi Dagher, Robert Justice, Richard Pazdur> ;The Oncologist. 2007 Jan 1
• An analysis of deficiencies identified during investigational new drug (IND) application reviews by the Division of Drug Oncology Products (DDOP) of the US FDA.
  Mann BS, Kane R, Brave M, Ryan Q, Hazarika M, Rock E, Senderowicz A, Dagher R, Johnson J, Justice R, Pazdur R> ;J. Clin. Oncol.. 2006-06-20
• Human chorionic gonadotropin free beta chain is a negative prognostic indicator in malignant carcinoid.
  Rock E, Levy D, Stuart K, Anderson T, Cole L> ;J. Clin. Oncol.. 2005-06-01
• 44 citations
  Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors
  Edwin P. Rock, Angela DeMichele> ;The Journal of Nutrition. 2003 Nov 1
• 7 citations
  Immunogenicity of a fusion protein linking the beta subunit carboxyl terminal peptide (CTP) of human chorionic gonadotropin to the B subunit of Escherichia coli heat-l...
  Edwin P. Rock, Karl A. Reich, Dennis M. Lyu, Marianne Hovi, Jonathan Hardy, Gary K. Schoolnik, Bruce A. D. Stocker, Vernon C. Stevens> ;Vaccine. 1996 Nov 1
• 2 citations
  Structural Analysis of the Carboxyl Terminal Peptide From Human Chorionic Gonadotropin β-Subunit by Two-Dimensional Nuclear Magnetic Resonance Spectroscopy
  Edwin P. Rock, Jerzy Czaplicki, Alain Milon> ;American Journal of Reproductive Immunology. 1996 Mar 1
• 408 citations
  CDR3 length in antigen-specific immune receptors.
  Edwin P. Rock, P. R. Sibbald, Mark M. Davis, Yueh-hsiu Chien> ;The Journal of Experimental Medicine. 1994 Jan 1
• 80 citations
  T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen.
  Elliot W. Ehrich, Brigitte Devaux, Edwin P. Rock, Jeffrey L. Jorgensen, Mark M. Davis, Yueh-hsiu Chien> ;The Journal of Experimental Medicine. 1993 Aug 1
• 74 citations
  Transfer of putative complementarity-determining region loops of T cell receptor V domains confers toxin reactivity but not peptide/MHC specificity.
  Phillip A. Patten, Edwin P. Rock, T Sonoda, B Fazekas de St Groth, Jeffrey L. Jorgensen, Mark M. Davis> ;Journal of Immunology. 1993 Mar 15
• 4 citations
  A Possible Basis for Major Histocompatibility Complex-Restricted T-Cell Recognition
  Mark M. Davis, Yueh-hsiu Chien, Pamela J. Bjorkman, John F. Elliott, Makio Iwashima, Edwin P. Rock, Phillip A. Patten> ;Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 1989 Jun 12
• Join now to see all